Sunny H. Kim

Sunny H. Kim

Auto-generated profile, based on publicly available information

Sunny H. Kim

Department of Pharmacology and Pharmaceutical Sciences Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California Los Angeles CA USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
LZLei Zhang
Lei Zhang
MAMashael F. Aldossari
Mashael F. Aldossari
AAArshad J. Ansari
Arshad J. Ansari
GKGuoyun Kao
Guoyun Kao
SKSunny H. Kim
Sunny H. Kim
YZYong Zhang
Yong Zhang
Antibody-drug conjugates (ADCs) bring superior efficacy and safety profiles to the clinic by harnessing the power of biologics and chemotherapy. Despite numerous ADCs at different preclinical and clinical stages, homogeneous ADC with increased numbers of payloads conjugated at specific positions are still desired for enhanced pharmacological properties. To generate site-specifically conjugated ADCs with greater drug-to-antibody ratios (DARs), monoclonal antibodies targeting prostate-specific membrane antigens (PSMA) were genetically fused with tandem CD38 enzymes, a member of the ADP-ribosyl cyclase family. The resulting antibody-CD38 fusions coupled with its dinucleotide substrate-derived drug linker facilitate generation of ADP-ribosyl cyclase-enable ADCs (ARC-ADCs) carrying 2, 4, 6, and 8 tubulin inhibitors. In vitro and in vivo studies indicated highly potent and selective cytotoxicity against human PSMA-expressing prostate cancer cells for the anti-PSMA ARC-ADC with a DAR of 6. This proof-of-concept study demonstrates feasibility of producing site-specific ARC-ADCs with increased DARs by tandemly fused CD38 and generates candidate ADCs for targeting prostate tumors.

21 December 2025 in Advanced Science
Verified
Journal Article
Open access
SKSunny H. Kim
Sunny H. Kim
AAArshad J. Ansari
Arshad J. Ansari
LZLei Zhang
Lei Zhang
GKGuoyun Kao
Guoyun Kao
THThuc Oanh Hoang
Thuc Oanh Hoang
YZYong Zhang
Yong Zhang
Armed with two distinct targeting moieties, artificially created bispecific agents can uniquely modulate various processes and events implicated in human health and diseases. Despite recent approvals of multiple bispecific therapeutics, generation of homogeneous dual‐targeting constructs with desired pharmacological properties remains technically challenging. Here, we report a strategy for synthesis of bispecific agents by utilizing CD38, a member of the ADP‐ribosyl cyclase family, and its covalent inhibitor. A model ADP‐ribosyl cyclase‐enabled bispecific conjugate (ARC‐BsC) against human T‐cell CD3 and prostate‐specific membrane antigen (PSMA) is generated through site‐specific conjugation of an anti‐CD3 antibody‐CD38 fusion with the CD38 covalent inhibitor derivatized by a PSMA small‐molecule ligand. The resulting ARC‐BsC can redirect and activate cytotoxic T cells toward killing PSMA‐expressing tumor cells, eliciting highly potent and selective anti‐cancer immunity in vitro and in vivo. This proof‐of‐concept work demonstrates ARC‐BsC as a potentially general approach for the development of bispecific therapeutics with diverse applications.